Stem-cell gene therapy for the Wiskott-Aldrich syndrome

New England Journal of Medicine

Volumn 363, Issue 20, 2010, Pages 1918-1927

  Boztug, Kaan ^a   Schmidt, Manfred ^b   Schwarzer, Adrian ^a   Banerjee, Pinaki P ^d   Díez, Inés Avedillo ^a   Dewey, Ricardo A ^a   Böhm, Marie ^a   Nowrouzi, Ali ^b   Ball, Claudia R ^b   Glimm, Hanno ^b   Naundorf, Sonja ^c   Kühlcke, Klaus ^c   Blasczyk, Rainer ^a   Kondratenko, Irina ^e   Maródi, László ^f   Orange, Jordan S ^d   Von Kalle, Christof ^b   Klein, Christoph ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c BIONTECH AG   (Germany)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e Russian Children's Clinical Hospital   (Russian Federation)

^f UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; BMI1 PROTEIN; BUSULFAN; CCND2 PROTEIN; CD19 ANTIGEN; CD34 ANTIGEN; FIBRINOGEN RECEPTOR ANTIBODY; GLYCOPROTEIN IB IX ANTIBODY; GLYCOPROTEIN V ANTIBODY; HNA 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LMO2 PROTEIN; MDS1 PROTEIN; PRDM16 PROTEIN; PROTEIN; SETBP1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; WISKOTT ALDRICH SYNDROME PROTEIN;

ALOPECIA; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLEEDING TENDENCY; BONE MARROW CELL; BONE MARROW SUPPRESSION; BRONCHITIS; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; ECZEMA; ENTEROCOLITIS; GENE MUTATION; GENE TRANSFER; GENETIC MODEL; HEMATOMA; HEMATOPOIESIS; HEMORRHAGIC COLITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE FUNCTION; LYMPHOID CELL; LYMPHOPOIESIS; MALE; MOLECULAR CLONING; MONOCYTE; MYELOPOIESIS; NATURAL KILLER CELL; NEUTROPENIA; OTITIS MEDIA; PETECHIA; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT INFECTION; REGULATORY T LYMPHOCYTE; RNA SPLICING; SALMONELLOSIS; SEPTICEMIA; SPLENECTOMY; STEM CELL GENE THERAPY; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; WISKOTT ALDRICH SYNDROME;

EID: 78149482538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1003548     Document Type: Article

References (25)

1. Puck JM, Candotti F. Lessons from the Wiskott-Aldrich syndrome. N Engl J Med 2006;355:1759-61.
2. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008;15:30-6.
3. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78:635-44.
4. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010;10:182-92.
5. Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009;113:6288-95.
6. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004;103:456-64.
7. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111:439-45.
8. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72.
9. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-93.
10. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-3.
11. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-58.
12. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
13. Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther 2006;8:390-5.
14. Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008;112:4139-47.
15. Klein C, Nguyen D, Lui C-H, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003;101: 2159-66.
16. Dewey RA, Avedillo Diez I, Ballmaier M, et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp Hematol 2006;34:1161-9.
17. Orange JS, Ramesh N, Remold- O'Donnell E, et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002;99:11351-6.
18. Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007;117:407-18.
19. Schmidt M, Schwarzwaelder K, Bartholomae C, et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007;4:1051-7.
20. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T-cell proliferations in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9. [Erratum, Science 2003;302: 568.]
21. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118: 3132-42.
22. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-50.
23. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204.
24. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-23.
25. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006;108:134-40.